Initial studies on small numbers of patients suggested that TNF-α blockade decreases circulating CD28null T-cell number in RA and UA.25,26 However, recent studies failed to show consistent depletion of this cell subset in RA patients treated with infliximab or etanercept for 1 year.27 Whether TNF-α inhibitors have beneficial effects in patients with coronary atherosclerosis remains to be established. Here, TNF is linked to coronary atherosclerosis.